This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Randomized Controlled Trial

. 2005 Nov-Dec;3(6 Suppl 4):10-1.

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy

Pamela S Hinds, Marilyn Hockenberry, James Feusner, Jeffrey D Hord, Wayne Rackoff, Bassem I Rozzouk

PMID: 16355549

Randomized Controlled Trial

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy

Pamela S Hinds et al. J Support Oncol. 2005 Nov-Dec.

. 2005 Nov-Dec;3(6 Suppl 4):10-1.

Authors

Pamela S Hinds, Marilyn Hockenberry, James Feusner, Jeffrey D Hord, Wayne Rackoff, Bassem I Rozzouk

PMID: 16355549

No abstract available

PubMed Disclaimer

Similar articles

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N, Sriuranpong V, Suwanrusme H. Voravud N, et al. J Med Assoc Thai. 2007 Jun;90(6):1082-8. J Med Assoc Thai. 2007. PMID: 17624200 Clinical Trial.
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
Osterborg A, Brandberg Y. Osterborg A, et al. Cancer. 2003 Jun 15;97(12):3125-6; author reply 3126-7. doi: 10.1002/cncr.11430. Cancer. 2003. PMID: 12784351 No abstract available.
Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR. Razzouk BI, et al. J Clin Oncol. 2006 Aug 1;24(22):3583-9. doi: 10.1200/JCO.2005.03.4371. J Clin Oncol. 2006. PMID: 16877725 Clinical Trial.
Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
Quirt I, Kovacs M, Couture F, Turner AR, Noble M, Burkes R, Dolan S, Plante RK, Lau CY, Chang J. Quirt I, et al. Oncologist. 2006 Jan;11(1):73-82. doi: 10.1634/theoncologist.11-1-73. Oncologist. 2006. PMID: 16401716 Review.
Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
Spaëth D. Spaëth D. Expert Rev Anticancer Ther. 2008 Jun;8(6):875-85. doi: 10.1586/14737140.8.6.875. Expert Rev Anticancer Ther. 2008. PMID: 18533797 Review.

See all similar articles

Cited by

Considering quality of life for children with cancer: a systematic review of patient-reported outcome measures and the development of a conceptual model.
Anthony SJ, Selkirk E, Sung L, Klaassen RJ, Dix D, Scheinemann K, Klassen AF. Anthony SJ, et al. Qual Life Res. 2014 Apr;23(3):771-89. doi: 10.1007/s11136-013-0482-x. Epub 2013 Aug 2. Qual Life Res. 2014. PMID: 23907613
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Bohlius J, et al. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD007303. doi: 10.1002/14651858.CD007303.pub2. Cochrane Database Syst Rev. 2009. PMID: 19588423 Free PMC article.
Erythropoietin or darbepoetin for patients with cancer.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Tonia T, et al. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5. Cochrane Database Syst Rev. 2012. PMID: 23235597 Free PMC article.
Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Adams A, Scheckel B, Habsaoui A, Haque M, Kuhr K, Monsef I, Bohlius J, Skoetz N. Adams A, et al. Cochrane Database Syst Rev. 2022 Jun 20;6(6):CD012633. doi: 10.1002/14651858.CD012633.pub2. Cochrane Database Syst Rev. 2022. PMID: 35724934 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information